TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03632447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leva
Description: Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFDx
Description: All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
Study: NCT02928497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Antiplatelet Therapy or No Therapy (Control)
Description: Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
Study: NCT01085253

Intervention type: OTHER
Intervention: 3T and 7T MR imaging
Description: all patients and controls will be explored using a 3T and 7T MR imaging

Intervention type: OTHER
Intervention: 3T and 7T MR imaging
Description: all patients and controls will be explored using a 3T and 7T MR imaging

Intervention type: OTHER
Intervention: 3T and 7T MR imaging
Description: all patients and controls will be explored using a 3T and 7T MR imaging
Study: NCT02020720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo image-guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-DOPA-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo DTI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorodopa
Description: Undergo 18F-DOPA-PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo pMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-DOPA-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo stereotactic craniotomy
Study: NCT03699319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613
Description: Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Intended treatment protocol is 12 cycles (2 weeks each) or 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered at 65 mg/m2 given as a 2-hr IV~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-flurouracil
Description: Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study: NCT02182245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02291250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar matched water with polycal OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups
Study: NCT04053296

Intervention type: OTHER
Intervention: Observational study
Description: We follow up the results of patients.
Study: NCT03163342

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Licensed seasonal influenza vaccine
Description: 20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
Study: NCT02185469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic retinopexy
Description: First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
Study: NCT03632447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFDx
Description: All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
Study: NCT02184260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02185469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy
Description: Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfur hexafluoride (SF6)
Study: NCT01932177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
Study: NCT02221921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroPort's Transcatheter Aortic Valve and Delivery System
Study: NCT02255292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol (CBD)
Description: Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study
Study: NCT02185469

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5/8-in 25-gauge needle
Study: NCT03755050

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected

Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected
Study: NCT00938795

Intervention type: OTHER
Group type: OTHER
Intervention: Uncertainty Management Intervention
Description: Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison Conditions for Liver Transplant
Description: Six 30-minute telephone calls that provide structured education about liver disease.
Study: NCT03392454

Intervention type: PROCEDURE
Intervention: T+LRTI
Description: T+LRTI is the most commonly used procedure, it removes the entire trapezium

Intervention type: PROCEDURE
Intervention: PT+TI
Description: The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
Study: NCT00272519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Intervention
Description: Developed to promote life skills among young adolescents perinatally infected with HIV
Study: NCT00407030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin) (240 Units)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin) (120 Units)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00235313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dose adjustment of nicotine replacement therapies
Description: Dose adjustment of nicotine replacement therapies
Study: NCT02185469

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: intraoperative laser retinopexy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: intraoperative laser retinopexy
Study: NCT01466166

Intervention type: BIOLOGICAL
Intervention: Pegloticase
Description: Pegloticase 8 mg intravenous every 2 weeks
Study: NCT03965169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone spinal surgery
Description: spinal surgery in prone position under general anesthesia
Study: NCT02537457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939)
Description: Rivaroxaban granule15mg for one day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Rivaroxaban tablet15mg for one day
Study: NCT00575159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT01232725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Donor Human Milk
Description: Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Donor Human Milk
Description: Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
Study: NCT02584985

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ETAP
Description: Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Transabdominal Laparoscopic Proctectomy
Description: Primary transabdominal laparoscopic approach
Study: NCT04673838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurodevelopmental therapy
Description: Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurodevelopmental therapy
Description: Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower extremity sensory training
Description: Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
Study: NCT01722006

Intervention type: BEHAVIORAL
Intervention: Pairing condition

Intervention type: BEHAVIORAL
Intervention: Pairing condition
Description: 20 mg methamphetamine or placebo on four 4-hour laboratory sessions
Study: NCT04194931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BCMA CAR-T cells and CD19 CAR-T cells
Description: Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
Study: NCT04199741

Intervention type: DRUG
Intervention: 89Zr-DFO-SC16.56
Description: Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.

Intervention type: DRUG
Intervention: 89Zr-DFO-SC16.56
Description: Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.

Intervention type: DRUG
Intervention: SC16.56, Phase I, Cohort 2
Description: 7.5mg
Study: NCT00235313

Intervention type: DRUG
Group type: OTHER
Intervention: nicotine patch
Description: normal following with a nicotine patch
Study: NCT04199741

Intervention type: DRUG
Intervention: SC16.56, Phase I, Cohort 3
Description: 22.5mg

Intervention type: DRUG
Intervention: SC16.56, Phase II
Description: Dose for Phase II will be determined by results from Phase I.
Study: NCT03975075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychophysiological monitoring
Description: 30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychophysiological monitoring
Description: 30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
Study: NCT01315574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Description: One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
Study: NCT01844076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine and Capecitabine
Description: The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine and Capecitabine
Description: The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine and Capecitabine
Description: The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine and Capecitabine
Description: The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
Study: NCT03975075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Description: Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
Study: NCT04544267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine, high-dose
Description: Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
Study: NCT03617198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4 CAR+CCR5 ZFN T-cells
Description: A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4 CAR+CCR5 ZFN T-cells
Description: A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
Study: NCT04544267

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine, standard dose
Description: Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
Study: NCT03523377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prolonged overnight fasting
Description: Three phone calls using motivational interviewing, support via SMS text.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Eat a heart-healthy diet and exercise for at least 30 minutes five days a week
Study: NCT01773473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Mix25
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Mix50
Description: Administered SC
Study: NCT03884634

Intervention type: DEVICE
Intervention: Dabir Micropressure Overlay
Description: The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off.
Study: NCT00644579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bLAC
Description: bLAC high and low dose and placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bLAC
Description: bLAC high and low dose and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02195830

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound of the inferior vena cava
Description: B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
Study: NCT01708226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Program
Description: Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
Study: NCT05069779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Oral administration of 10 mg of diazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diazepam
Description: Oral administration of 10 mg of diazepam
Study: NCT04002687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV-PG 1000-400 mg + AQ 612 mg
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV-PG 1000-400 mg + AQ 612 mg
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
Study: NCT03136627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
Study: NCT04002687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV-PG 1000-400 mg + AQ 612 mg
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATV-PG 1000-400 mg + AQ 612 mg
Description: The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
Study: NCT01400828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 20 mg (encapsulated) tablets QD/14 days